Letter to Shareholders From Imagenetix, Inc. President/CEO Willi...(addition we anticipate receiving news sh...),Health

Date:8/26/2009

addition, we anticipate receiving news shortly on our patent associated with this compound. We also have contracted with an internationally respected Clinical Research Organization (CRO) to provide Imagenetix specific time lines to achieve drug approval from the FDA.

InflameAway Celadrin(R)

InflameAway Celadrin(R) extra strength soft gels for joint health are currently available at the nation's number one drug chain, the number one and number two supermarket stores and the number one club warehouse store. This retail distribution provides a platform for future retail gains as well as additional product launches, including a 100 count value size.

We have recently expanded our successful 15 and 30 second television ad spots for InflameAway Celadrin(R) to national audiences via cable as the primary driver of retail turnover. Starting August 10th, InflameAway Celadrin(R) can be seen on networks such as FOX news, CNN, USA and Hallmark. The spots will emphasize the theme of InflameAway Celadrin(R) being "6x Faster and More Effective" than Glucosamine and Chondroitin in promoting joint health. The campaign will also include compelling "actual user" testimonials as further evidence of brand performance and efficacy. This consumer campaign is intended to position InflameAway Celadrin(R) for rapid acceptance during the balance of this year and into 2010 - with the goal of obtaining loyal advocates of InflameAway Celadrin(R). Repeat customers, product compliance and beneficial results are core strengths of the InflameAway Celadrin(R) brand.

You can view these television spots by following these links:

http://www.larrychendesign.com/Celadrin_15_second_tv.wmv

SOURCE Imagenetix, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Tone Deafness Explained, from the Harvard Health Letter
4. CEL-SCI Corporation Releases Letter to Shareholders
5. For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter
6. An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R)
7. Strykers Biotech Division Receives FDA Warning Letter
8. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
9. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
10. U.S. FDA Issues Action Letter for Sugammadex
11. September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging